MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated

MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated

Metastatic melanoma presents, in many cases, oncogenic mutations in BRAF, a MAPK involved in proliferation of tumour cells. BRAF inhibitors, used as therapy in patients with these mutations, often lead to tumour resistance and, thus, the use of MEK inhibitors was introduced in clinics. BRAFi/MEKi, a...

Full description

Bibliographic Details
Main Authors: Silvia López-Borrego, Carmen Campos-Silva, Amaia Sandúa, Tamara Camino, Lucía Téllez-Pérez, Estibaliz Alegre, Alexandra Beneitez, Ricardo Jara-Acevedo, Annette Paschen, María Pardo, Álvaro González, Mar Valés-Gómez
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
metastatic melanoma
targeted cancer therapy
immunomodulation
immune evasion
extracellular vesicles
metalloproteases
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2022.1055288/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2022.1055288/full

Similar Items